• Discovering & developing proprietary prodrugs

    Our products have improved properties over approved drugs and address unmet medical needs in large, established markets.

  • Creating a diverse pipeline of prodrug therapeutics

    We employ our LAT™ (Ligand Activated Therapy) platform technology to improve the attributes of approved drugs.

  • Decades of experience in devising elegant solutions

    KemPharm® continues to implement its LAT™ platform technology to create prodrugs that are new molecules by chemically attaching ligand(s) to the parent drug.

Our Value Proposition

KemPharm® believes that its LAT™ Platform technology offers potential benefits to improve drug properties by developing prodrugs that are new molecules with improved attributes over FDA-approved drugs, such as enhanced bioavailability, extended duration of action, increased safety, and reduced susceptibility to abuse.

Learn More

KemPharm’s pipeline consists of multiple programs targeting opportunities in ADHD, pain, and CNS indications.

We employ our LAT™ (Ligand Activated Therapy) platform technology to improve the attributes of approved drugs.

Learn more about LAT™

July 9, 2018

Featured Publication

KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD; KP415 Successfully Meets Primary Efficacy Endpoint

Results from Single Classroom-Style Trial Met Pre-Specified Primary and Secondary Endpoint  Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 8:00 a.m. ET Coralville, IA – July 9, 2018 – KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today […]

keep reading

KemPharm® Company Overview
KemPharm® Company Culture
  • KemPharm Announces Positive, Topline Results ...

  • KemPharm, Inc. to Report First Quarter 2018 R...